ResMed Inc.

ResMed Inc.

ResMed Inc. (RMD) is a global medical‑technology company best known for devices that treat sleep apnoea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It sells CPAP machines, masks, ventilators and a growing suite of cloud-connected software and services aimed at long‑term patient management. Revenue mixes device sales, consumables and recurring digital subscriptions β€” a model that can support predictable cash flow as the installed base and mask/consumable replacements continue. Key attractions for investors include an ageing population, steady demand for sleep solutions, and ResMed’s push into remote-monitoring and digital health. Risks include reimbursement changes, competition from other device makers, supply‑chain pressures and regulatory approvals; performance can vary and past results do not guarantee future returns. Market cap is about $39.1bn, making it a large-cap healthcare name. This is general educational information, not personalised advice β€” consider your personal circumstances and tolerance for volatility before investing.

Why It's Moving

ResMed Inc.

ResMed Faces Mixed Analyst Signals as 2026 Price Targets Diverge Sharply.

Wall Street analysts show split views on ResMed, with some forecasting robust upside into 2026 amid steady EPS growth projections around $11.12, while others temper enthusiasm with more modest targets. This divergence reflects broader debates on sleep apnea device demand and competitive pressures in the medtech space, keeping investors on edge.
Sentiment:
βš–οΈNeutral
  • Analysts project average 2026 EPS of $11.12, ranging from $10.14 to $11.78, signaling confidence in earnings expansion despite sector headwinds.
  • Price targets for RMD vary widely, from $265 lows to $345 highs, with averages between $266 and $303 hinting at 15-30% potential from current levels.
  • Recent ratings include upgrades like RBC Capital's to Sector Perform and Mizuho's Outperform maintain, balanced by past downgrades, underscoring volatile consensus.

When is the next earnings date for ResMed Inc. (RMD)?

ResMed's next earnings date is April 23, 2026, covering the third quarter of fiscal year 2026 (ending March 31, 2026). This follows the company's pattern of reporting approximately one month after quarter-end, with Q2 FY2026 results released on January 29, 2026. Investors should monitor official announcements for confirmation and webcast details.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying ResMed's stock, indicating expected growth towards a higher target price.

Above Average

Financial Health

ResMed is performing well with strong revenue and cash flow, indicating good financial stability.

Below Average

Dividend

ResMed's dividend yield of 0.92% is below average, which may not appeal to dividend-seeking investors. If you invested $1000 you would be paid $9.20 a year in dividends (based on the last 12 months).

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring RMD

Wearable Health Stocks: Growth Potential vs Competition

Wearable Health Stocks: Growth Potential vs Competition

Apple's recent FDA clearance for its Apple Watch hypertension feature marks a major step in wearable medical technology. This development opens up investment opportunities in the broader ecosystem of connected health devices and remote patient monitoring services.

Published: September 12, 2025

Explore Basket
Rest & Recharge

Rest & Recharge

Tap into the booming wellness economy with companies revolutionizing how we sleep and relax. These carefully selected stocks represent innovative leaders in sleep technology, relaxation services, and wellness solutions that are responding to our growing desire for better rest and recovery.

Published: June 17, 2025

Explore Basket
Rest & Recovery

Rest & Recovery

This carefully curated collection features companies at the forefront of sleep science and recovery technology. These stocks represent a growing market where innovation meets wellness, selected by professional analysts tracking the expanding health optimization trend.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

πŸ“ˆ

Recurring revenue model

ResMed’s mix of devices plus consumables and subscriptions can create steadier cash flows, though revenues still face reimbursement and demand risks.

🌍

Global patient base

An ageing population and rising diagnosis of sleep disorders support long-term demand, but regional regulation and payor policies can affect growth.

⚑

Connected‑care push

Investment in cloud platforms and remote monitoring could boost stickiness and services revenue, yet technology adoption and competition may vary.

Why invest with Nemo?

Nemo Logo Fade
πŸ†“

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

πŸ”’

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

πŸ’°

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

ABT

Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

A

Agilent Technologies Inc.

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.

ALGN

Align Technology Inc.

Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.

Frequently asked questions